Short Interest in XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Drops By 97.2%

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) was the target of a large decrease in short interest in the month of May. As of May 15th, there was short interest totaling 19,218 shares, a decrease of 97.2% from the April 30th total of 680,467 shares. Based on an average daily trading volume, of 239,726 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.2% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a report on Thursday, April 2nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

XTL Biopharmaceuticals Stock Up 1.0%

Shares of XTL Biopharmaceuticals stock traded up $0.03 on Thursday, reaching $2.47. The stock had a trading volume of 5,237 shares, compared to its average volume of 1,284,475. The company has a 50 day moving average price of $2.59 and a 200 day moving average price of $5.45. XTL Biopharmaceuticals has a 1 year low of $2.12 and a 1 year high of $10.28. The stock has a market capitalization of $5.42 million, a P/E ratio of -3.85 and a beta of 1.64.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.